Contribution of serum protein association to discrepancy between the in vivo and in vitro UDS results for 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843)

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 395, Issue 2-3, 1997, Pages 119-126

  Zhao, Zhiyang ^a   Koeplinger, Kenneth A ^a   Padbury, Guy E ^a   Aaron, Charles S ^a   Harbach, Philip R ^a   Mayo, Judy K ^a   Mattes, William B ^a   Bundy, Gordon L ^a  

^a PFIZER INC   (United States)

Author keywords

Genetic toxicity; In vivo, in vitro; Intrinsic clearance; Metabolism; Protein association; Reactive metabolite; UDS mutagenesis

Indexed keywords

ANTIOXIDANT; DRUG METABOLITE; PLASMA PROTEIN; PYRIMIDINE DERIVATIVE; U 89843; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DRUG CLEARANCE; DRUG METABOLISM; GENOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLIC ACTIVATION; MUTAGENICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; UNSCHEDULED DNA SYNTHESIS;

ANIMALS; BLOOD PROTEINS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; LIVER; MALE; MICROSOMES, LIVER; MUTAGENICITY TESTS; PYRIMIDINES; PYRROLES; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; SERUM ALBUMIN, BOVINE;

ANIMALIA; BOVINAE;

EID: 0031565970     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(97)00152-6     Document Type: Article

References (12)

1. Gutteridge J.M. Free radicals in disease processes: A compilation of cause and consequence. Free Radic. Res. Commun. 19:1993;141-158.
2. Maxwell S.R.J. Prospects for the use of antioxidant therapies. Drugs. 49:1995;345-361.
3. Bundy G.L., Ayer D.E., Banitt L.S., Belonga K.L., Mizsak S.A., Palmer J.R., Tustin J.M., Chin J.E., Hall E.D., Linseman K.L., Richards I.M., Scherch H.M., Sun F.F., Yonkers P.A., Larson P.G., Lin J.M., Padbury G.E., Aaron C.S., Mayo J.K. Synthesis of novel 2,4-diaminopyrrolo[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity. J. Med. Chem. 38:1995;4161-4163.
4. Zhao Z., Koeplinger K.A., Bundy G.L., Banitt L.S., Padbury G.E., Hauer M.J., Sanders P.E. In vitro and in vivo biotransformation of 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) in the rat. Drug. Metab. Dispos. 24:1996;187-198.
5. Zhao Z., Koeplinger K.A., Padbury G.E., Hauer M.J., Bundy G.L., Banitt L.S., Schwartz T.M., Zimmermann D.C., Aaron C.S., Harbach P.R., Mayo K. Bioactivation of 6,7-Dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) to reactive intermediates that bind covalently to macromolecules and produce genotoxicity. Chem. Res. Toxicol. 9:1996;1230-1239.
6. Mirsalis J.C., Butterworth B.E. Detection of unscheduled DNA synthesis in hepatocytes isolated from rats treated with genotoxic agents: An in vivo-in vitro assay for potential carcinogens and mutagens. Carcinogenesis. 1:1980;621-625.
7. Mirsalis J.C., Tyson C.K., Butterworth B.E. Induction of DNA repair in hepatocytes from rats treated in vivo with genotoxic agents. Environ. Mutagen. 4:1982;553-562.
8. Lu A.Y., Levin W. Partial purification of cytochromes P-450 and P-448 from rat liver microsomes. Biochem. Biophys. Res. Commun. 46:1972;1334-1339.
9. Pinkerton T.C., Koeplinger K.A. Determination of warfarin-human serum albumin protein binding parameters by an improved Hummel-Dreyer high-performance liquid chromatographic method using internal surface reversed phase columns. Anal. Chem. 162:1990;2114-2122.
10. Kennelly J.C. Design and interpretation of rat liver UDS assays. Mutagenesis. 10:1995;215-221.
11. Tietz, N.W. (Ed.), Fundamentals of Clinical Chemistry, Saunders, Philadelphia, 1982, pp. 298-306.
12. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1994;1469-1479.